Search our Site:

sitemap


LIPOSOMES - MACROPHAGE DEPLETION- ANTICANCER DRUGS - ANTIVIRAL DRUGS - CONTRAST AGENTS - CLINICAL TRIALS
List of Publications: R. Schwendener
  1. Sequential Activation of Two Pathogen-Sensing Pathways Required for Type I Interferon Expression and Resistance to an Acute DNA Virus Infection. Xu RH, Wong EB, Rubio D, Roscoe F, Ma X, Nair S, Remakus S, Schwendener R, John S, Shlomchik M, Sigal LJ. Immunity 43(6):1148-59, 2015. PMID: 26682986

  2. Cross-talk between tumors can affect responses to therapy. Devaud C, John LB, Westwood JA, Yong CSM, Beavis PA, Schwendener RA, Darcy PK, Kershaw MH. Oncoimmunology 7:e975572, 2015. DOI:10.4161/2162402X.2014.975572. PMID: 26140251

  3. Intravital and whole-organ imaging reveals capture of melanoma-derived antigen by lymph node subcapsular macrophages leading to widespread deposition on follicular dendritic cells. Moalli F, Proulx ST, Schwendener R, Detmar M, Schlapbach C, Stein JV. Front Immunol. 6:114, 2015. doi: 10.3389/fimmu.2015.00114. eCollection 2015. PMID: 25821451

  4. ATG16L1 deficiency in macrophages drives clearance of uropathogenic E. coli in an IL-1β-dependent manner. Symington JW, Wang C, Twentyman J, Owusu-Boaitey N, Schwendener R, Nunez G, Schilling JD, Mysorekar IU. Mucosal Immunol. 8(6):1388-99, 2015. doi: 10.1038/mi.2015.7. PMID: 25669147

  5. Liposomes as vaccine delivery systems: A review of the recent advances. Schwendener RA. Therapeutic Advances in Vaccines 2:159-182, 2014. PMID: 25364509

  6. A New Approach to Cancer Therapy: The Tumor Microenvironment as Target. Schwendener RA, Mete S. Frontiers in Clinical Drug Research - Anti-Cancer Agents, Volume 1, Pp. 3-68, 2014. (Edited by Atta-ur-Rahman), DOI: 10.2174/97816080579861130101, ISBN: 978-1-60805-799-3.

  7. Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis. Hannan TJ, Roberts PL, Riehl TE, van der Post S, Binkley JM, Schwartz DJ, Miyoshi H, Mack M, Schwendener RA, Hooton TM, Stappenbeck TS, Hansson GC, Stenson WF, Colonna M, Stapleton AE, Hultgren SJ. eBioMedicine 1, p46-57, 2014; DOI: http://dx.doi.org/10.1016/j.ebiom.2014.10.011. PMID: 26125048

  8. Heat Shock Protein-Mediated Protection Against Cisplatin-Induced Hair Cell Death. Baker TG, Roy S, Brandon CS, Kramarenko IK, Francis SP, Taleb M, Marshall KM, Schwendener R, Lee FS, Cunningham LL. J Assoc Res Otolaryngol. 2014 Sep 27. PMID: 25261194

  9. Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells. Sabatino R, Antonelli A, Battistelli S, Schwendener R, Magnani M, Rossi L. PLoS One 9(6):e101260, 2014. PMID: 24968029

  10. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. Downey CM, Aghaei M, Schwendener RA, Jirik FR. PLoS One. 9(6):e99988, 2014. PMID: 24940883

  11. Depletion of cutaneous macrophages and dendritic cells promotes growth of Basal Cell Carcinoma in mice. Koenig S, Nitzki F, Uhmann A, Dittmann K, Theiss-Suennemann J, Herrmann M, Reichardt HM, Schwendener R, Pukrop T, Schulz-Schaeffer W, Hahn H. PLoS One 9(4):e93555, 2014. PMID: 24691432

  12. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, Brija T, Gautier EL, Ivanov S, Satpathy AT, Schilling JD, Schwendener R, Sergin I, Razani B, Forsberg EC, Yokoyama WM, Unanue ER, Colonna M, Randolph GJ, Mann DL. Immunity. 40(1):91-104, 2014. PMID: 24439267

  13. The depletion of donor macrophages reduces ischaemia-reperfusion injury after mouse lung transplantation. Tsushima Y, Jang JH, Yamada Y, Schwendener R, Suzuki K, Weder W, Jungraithmayr W. Eur J Cardiothorac Surg. 45(4):703-9, 2014. PMID: 24113322

  14. Macrophage and T cell produced IL-10 promotes viral chronicity. Richter K, Perriard G, Behrendt R, Schwendener RA, Sexl V, Dunn R, Kamanaka M, Flavell RA, Roers A, Oxenius A. PLoS Pathog.9(11):e1003735, 2013. PMID: 24244162

  15. Empty liposomes induce antitumoral effects associated with macrophage responses distinct from those of the TLR1/2 agonist Pam3CSK 4 (BLP). Koenig S, Regen T, Dittmann K, Engelke M, Wienands J, Schwendener R, Hanisch UK, Pukrop T, Hahn H.Cancer Immunol Immunother. 2013 Oct;62(10):1587-97, 2013. PMID: 23917775

  16. Depletion of resident macrophages does not alter sensory regeneration in the avian cochlea. Warchol ME, Schwendener RA, Hirose K. PLoS One. 7(12): e51574, 2012. PMID: 23240046

  17. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. Jurgeit A, McDowell R, Moese S, Meldrum E, Schwendener R, Greber, UF. PLoS Pathog 8(10): e1002976, 2012. PMID: 23133371

  18. Microparticles released by Listeria monocytogenes-infected macrophages are required for dendritic cell-elicited protective immunity. Zhang Y, Zhang R, Zhang H, Liu J, Yang Z, Xu P, Cai W, Lu G, Cui M, Schwendener RA, Shi HZ, Xiong H, Huang B. Cell Mol Immunol. 9, 489, 2012. PMID: 23064105

  19. Macrophages modulate cardiac function in lipotoxic cardiomyopathy. Schilling JD, Machkovech H, Kim AH, Schwendener R, Schaffer JE. Am J Physiol Heart Circ Physiol 303:H1366, 2012. PMID: 23042950

  20. Inhibition of the Kit ligand/c-Kit axis attenuates metastasis in a mouse model mimicking local breast cancer relapse after radiotherapy. Kuonen F, Laurent J, Secondini C, Lorusso G, Stehle JC, Rausch T, Faes-Van't Hull E, Bieler G, Alghisi GC, Schwendener R, Andrejevic-Blant S, Mirimanoff RO, Ruegg C. Clin Cancer Res. 18(16):4365, 2012. PMID: 22711708

  21. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H, Schwendener R, Pruschy M, Knuth A, van den Broek M. J Immunol. 189(2):558-66, 2012. PMID: 22685313

  22. Dichotomy between RIP1- and RIP3-mediated necroptosis in tumor necrosis factor a-induced shock. Linkermann A, Braesen JH, De Zen F, Weinlich R, Schwendener RA, Green DR, Kunzendorf U, Krautwald S. Mol Med.18(1):577-86, 2012. PMID: 22371307

  23. A rational design for the nanoencapsulation of poisonous animal venoms in liposomes prepared with natural phospholipids. da Costa MH, Sant'anna OA, Quintilio W, Schwendener RA, de Araujo PS. Curr Drug Deliv. 9: 637, 2012. PMID: 22283655

  24. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener R. BMC Cancer. 12(1):35, 2012. PMID: 22273460

  25. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnes CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, Vergilio JA, Pietramaggiori G, Scherer-Pietramaggiori SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthati VL, Ingber DE, Kaipainen A, D'Amore PA, Kieran MW, Zeldin DC. J Clin Invest. 122(1):178-91, 2012. PMID: 22182838

  26. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P, Schwendener RA, Bai XF, Shilo K, Zou X, Leone G, Wolf R, Yuspa SH, Ganju RK. Cancer Res. 72(3):604-15, 2012. PMID:22158945

  27. Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Lee YS, Li P, Huh JY, Hwang IJ, Lu M, Kim JI, Ham M, Talukdar S, Chen A, Lu WJ, Bandyopadhyay GK, Schwendener R, Olefsky J, Kim JB. Diabetes 60: 2474-2483, 2011. PMID:21911747

  28. Albumin coated liposomes: a novel platform for macrophage specific drug delivery. Vuarchey C, Kumar S, Schwendener R. Nanotechnology Development 1:e2, 2011. PMID:

  29. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages. Borborema SE, Schwendener RA, Osso Junior JA, de Andrade Junior HF, do Nascimento N. Int J Antimicrob Agents. 38(4):341-7, 2011. PMID: 21783345

  30. Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. Rizzo A, Monteleone I, Fina D, Stolfi C, Caruso R, Fantini MC, Franze E, Schwendener R, Pallone F, Monteleone G. Inflamm Bowel Dis. 18:449, 2012. PMID: 21688353

  31. N4-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-New drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate). Schott H, Goltz D, Schott TC, Jauch C, Schwendener RA. Bioorg Med Chem. 19(11):3520-6, 2011. PMID: 21536448

  32. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Yang H, Kim C, Kim MJ, Schwendener RA, Alitalo K, Heston W, Kim I, Kim WJ, Koh GY. Mol. Cancer 10(1):36, 2011. PMID: 21481239

  33. Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy. Zattoni M, Mura ML, Deprez F, Schwendener RA, Engelhardt B, Frei K, Fritschy J-M. J. Neuroscience 31(11):4037, 2011. PMID: 21411646

  34. Nitric oxide short-circuits interleukin-12-mediated tumor regression. Egilmez NK, Harden JL, Virtuoso LP, Schwendener RA, Kilinc MO. Cancer Immunol Immunother. 60(6):839-45, 2011. PMID: 21387108

  35. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. Haynes NM, Hawkins ED, Li M, McLaughlin NM, Haemmerling GJ, Schwendener R, Winoto A, Wensky A, Yagita H, Takeda K, Kershaw MH, Darcy PK, Smyth MJ. J Immunol. 185(1):532-41, 2010. PMID: 20505139

  36. Inadequate clearance of translocated bacterial products in HIV-infected humanized mice. Hofer U, Schlaepfer E, Baenziger S, Nischang M, Regenass S, Schwendener R, Kempf W, Nadal D, Speck RF. PLoS Pathog. 6(4):e1000867, 2010. PMID: 20442871

  37. In vivo bioluminescence imaging and histopathopathologic analysis reveal distinct roles for resident and recruited immune effector cells in defense against invasive aspergillosis. Ibrahim-Granet O, Jouvion G, Hohl TM, Droin-Bergere S, Philippart F, Kim OY, Adib-Conquy M, Schwendener R, Cavaillon JM, Brock M. BMC Microbiol. 10(1):105, 2010. PMID: 20377900

  38. Liposome-based vaccines. Schwendener RA, Ludewig B, Cerny A, Engler O. Methods Mol Biol 605:163-75, 2010. PMID: 20072880

  39. Liposome formulations of hydrophobic drugs. Schwendener RA, Schott H. Methods Mol Biol 605:129-38, 2010. PMID: 20072877

  40. Toll-like receptor triggering and T-cell costimulation induce potent antitumor immunity in mice. Westwood JA, Haynes NM, Sharkey J, McLaughlin N, Pegram HJ, Schwendener RA, Smyth MJ, Darcy PK, Kershaw MH. Clin Cancer Res 15(24):7624, 2009. PMID: 19762711

  41. Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine. Bijnsdorp IV, Schwendener RA, Schott H, Fichtner I, Smid K, Laan AC, Schott S, Losekoot N, Honeywell RJ, Peters GJ. Invest New Drugs. 29(2):248-57, 2011. PMID: 19957099

  42. Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding. Schott H, Schott S, Schwendener RA. Bioorg Med Chem 17(19):6824-31, 2009. PMID: 19744858

  43. Role of CD11b+ macrophages in intraperitoneal lipopolysaccharide-induced aberrant lymphangiogenesis and lymphatic function in the diaphragm. Kim KE, Koh YJ, Jeon BH, Jang C, Han J, Kataru RP, Schwendener RA, Kim JM, Koh GY. Am J Pathol. 175(4):1733-1745, 2009. PMID: 19762711

  44. Myeloid cells contribute to tumor lymphangiogenesis. Zumsteg A, Baeriswyl V, Imaizumi N, Schwendener R, Ruegg C, Christofori G. PLoS One 4(9):e7067, 2009. PMID: 19759906

  45. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Torroella-Kouri M, Silvera R, Rodriguez D, Caso R, Shatry A, Opiela S, Ilkovitch D, Schwendener RA, Iragavarapu-Charyulu V, Cardentey Y, Strbo N, Lopez DM. Cancer Res 69: 4800-09, 2009. PMID: 19458073

  46. The CD4+ T cell-mediated IFN-gamma response to Helicobacter infection is essential for clearance and determines gastric cancer risk. Sayi A, Kohler E, Hitzler I, Arnold I, Schwendener R, Rehrauer H, Mueller A. J Immunol 182(11): 7085-101, 2009. PMID: 19454706

  47. Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Kataru RP, Jung K, Jang C, Yang H, Schwendener RA, Baik JE, Han SH, Alitalo K, Koh GY. Blood 113: 5650-59, 2009. PMID: 19346498

  48. Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. Schott H, Hamprecht K, Schott S, Schott TC, Schwendener RA. Bioorg Med Chem 17(1): 303-10, 2009. PMID: 19010684

  49. IL-12 p80-dependent macrophage recruitment primes the host for increased survival following a lethal respiratory viral infection. Gunsten S, Mikols CL, Grayson MH, Schwendener RA, Agapov E, Tidwell RM, Cannon CL, Brody SL, Walter MJ. Immunology 126(4): 500-13, 2009. PMID: 18783467

  50. A pro-inflammatory signature mediates FGF2-induced angiogenesis. Andres G, Leali D, Mitola S, Coltrini D, Camozzi M, Corsini M, Belleri M, Hirsch E, Schwendener RA, Christofori G, Alcami A, Presta M. J Cell Mol Med 13(8b): 2083-2108, 2009. PMID: 18624773

  51. Gene transfer may be preventive but not curative for a lysosomal transport disorder. Hippert C, Dubois G, Morin C, Disson O, Ibanes S, Jacquet C, Schwendener R, Antignac C, Kremer EJ, Kalatzis V. Mol Ther 16(8): 1372-81, 2008. PMID: 18578013

  52. Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg. Kim DD, Miwa T, Kimura Y, Schwendener RA, van Lookeren Campagne M, Song WC. Blood 112(4): 1109-19, 2008. PMID: 18524992

  53. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, Benoit LA, Byers DE, Alevy Y, Tucker J, Swanson S, Tidwell R, Tyner JW, Morton JD, Castro M, Polineni D, Patterson GA, Schwendener RA, Allard JD, Peltz G, Holtzman MJ. Nat Med 14(6): 633-40, 2008. PMID: 18488036

  54. Morphine induces defects in early response of alveolar macrophages to Streptococcus pneumoniae by modulating TLR9-NF-{kappa}B signaling Wang J, Barke RA, Charboneau R, Schwendener R, Roy S. J Immunol 180(5): 3594-600, 2008. PMID: 18292587

  55. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS, Alitalo K, Koh GY. Cancer Res 68(4): 1100-1109, 2008. PMID: 18281485

  56. Neuroprotective and axon growth promoting effects of intraocular inflammation do not depend on oncomodulin or the presence of large numbers of activated macrophages. Hauk TG, Muller A, Lee J, Schwendener R, Fischer D. Exp Neurol 209(2): 469-82, 2008. PMID: 18021771

  57. Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model. Ren W, Markel DC, Schwendener R, Ding Y, Wu B, Wooley PH. J Biomed Mater Res A 85(4): 1043-51, 2008. PMID: 17937417

  58. Interaction between macrophages, TGF-beta1, and the COX-2 pathway during the inflammatory phase of skeletal muscle healing after injury. Shen W, Li Y, Zhu J, Schwendener R, Huard J. J Cell Physiol 214(2): 405-12, 2008. PMID: 17657727

  59. Liposomes in biology and medicine. Schwendener RA. Adv Exp Med Biol 620: 117-28, 2007. PMID: 18217339

  60. In vivo and in vitro activity and mechanism of action of the multidrug cytarabine-L-glycerylyl-fluorodeoxyuridine. Bijnsdorp IV, Schwendener RA,Schott H, Fichtner I, Smid K, Schott S, Laan AC, Peters GJ. Nucleosides Nucleotides Nucleic Acids 26(10): 1619-24, 2007. PMID: 18066839

  61. Evaluation of anti-VEGFR-3 specific scFv antibodies as potential therapeutic and diagnostic tools for tumor lymph-angiogenesis. Zehnder-Fjallman AH, Marty C, Halin C, Hohn A, Schibli R, Ballmer-Hofer K, Schwendener RA. Oncol Rep 18(4): 933-41, 2007. PMID: 17786357

  62. Angiogenic role of LYVE-1-positive macrophages in adipose tissue. Cho CH, Koh YJ, Han J, Sung HK, Jong Lee H, Morisada T, Schwendener RA, Brekken RA, Kang G, Oike Y, Choi TS, Suda T, Yoo OJ, Koh GY. Circ Res 100(4): e47-57, 2007. PMID: 17272806

  63. Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury. Frank JA, Wray CM, McAuley DF, Schwendener R, Matthay MA. Am. J. Physiol. Lung Cell Mol. Physiol. 291(6):L1191-8, 2006. PMID: 16832418

  64. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA., Br J Cancer 95: 272-281, 2006. PMID: 16832418

  65. Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with pneumocystis pneumonia. Lasbury ME, Durant PJ, Ray CA, Tschang D, Schwendener R, Lee CH, J Immunol 176(11): 6443-53, 2006. PMID: 16709801

  66. CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Tyner JW, Uchida O, Kajiwara N, Kim EY, Patel AC, O'Sullivan MP, Walter MJ, Schwendener RA, Cook DN, Danoff TM, Holtzman MJ. Nat Med 11: 1180-1187, 2005. PMID: 16208318

  67. Optimizing photodynamic therapy: In vivo pharmacokinetics of liposomal meta-(tetrahydroxyphenyl)chlorin in feline squamous cell carcinoma. Buchholz J, Kaser-Hotz B, Khan T, Rohrer Bley C, Melzer K, Schwendener RA, Roos M, Walt H. Clin Cancer Res 11(20): 7538-44, 2005. PMID: 16243829

  68. Pulmonary aspiration: New therapeutic approaches in the experimental model. Beck-Schimmer B, Rosenberger DS, Neff SB, Jamnicki M, Suter D, Fuhrer T, Schwendener R, Booy C, Reyes L, Pasch T, Schimmer RC. Anesthesiology 103(3): 556-566, 2005. PMID: 16129981

  69. Histological analysis of CD11c-DTR/GFP mice after in vivo depletion of dendritic cells. Probst HC, Tschannen K, Odermatt B, Schwendener R, Zinkernagel RM, Van den Broek M., Clin Exp Immunol 141(3): 398-404, 2005. PMID: 16045728

  70. Alveolar macrophages regulate neutrophil recruitment in endotoxin-induced lung injury. Beck-Schimmer B, Schwendener R, Pasch T, Reyes L, Booy C, Schimmer RC., Respir Res 6(1):61, 2005. PMID: 15972102

  71. Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I. Robinson JA, Shankaramma SC, Jetter P, Kienzl, U, Schwendener RA, Vrijbloed JW, Obrecht, D., Bioorg Med Chem 13(6): 2055-64, 2005. PMID: 15727859

  72. Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs. Ludwig PS, Schwendener RA, Schott, H., Eur J Med Chem 40(5): 494-504, 2005. PMID: 15893023

  73. Lipophilic arabinofuranosyl cytosine derivatives in liposomes. Schwendener RA, Schott H., Methods Enzymol 391: 58-70, 2005. PMID: 15721374

  74. Targeting human cancer cells with VEGF receptor-2-directed liposomes. Demirovic AR, Marty C, Console S, Zeisberger SM, Ruch C, Jaussi R, Schwendener RA, Ballmer-Hofer K., Oncol Rep 13(2): 319-24, 2005. PMID: 15643518

  75. Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Marty C, Langer-Machova Z, Sigrist S, Schott H, Schwendener RA, Ballmer-Hofer K. Cancer Lett. 235(2):298-308, 2005. PMID: 15953677

  76. Cytotoxic tumor targeting with scFv antibody-modified liposomes. Marty C, Schwendener RA. Methods Mol Med 109: 389-402, 2005. PMID: 15585933

  77. A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Engler OB, Schwendener RA, Dai Wen J, Woelk B, Pichler W, Moradpour D, Brunner T, Cerny A., Vaccine 23: 58-68, 2004. PMID: 15519708

  78. Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Marty C, Meylan C, Schott H, Ballmer-Hofer K, Schwendener RA., Cell Mol Life Sci 61(14): 1785-94, 2004. PMID: 15241554

  79. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. J Immunol 172: 1777-1785, 2004. PMID: 14734761

  80. Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses. Aichele P, Zinke J, Grode L, Schwendener RA, Kaufmann SHE, Seiler P. J Immunol 171(3): 1148-1155, 2003. PMID:12874200

  81. Antennapedia and HIV transactivator of transcription (TAT) protein transduction domains promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. Console S, Marty C, Garcia-Echeverria C, Schwendener RA, Ballmer-Hofer K. J Biol Chem 278(37): 35109-14, 2003. PMID:12837762

  82. Decreased alveolar oxygen induces lung inflammation. Madjdpour C, Jewell UR, Kneller S, Ziegler U, Schwendener R, Booy C, Klausli L, Pasch T, Schimmer RC, Beck-Schimmer B., Am J Physiol Lung Cell Mol Physiol 284(2): L360-7, 2003. PMID: 12388372

  83. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Marty C, Odermatt B, Schott H, Neri D, Ballmer-Hofer K, Klemenz R, Schwendener RA. Br J Cancer 87(1): 106-12, 2002. PMID: 12085265

  84. In vitro activity of liposomal N4-octadecyl-1-b-D-arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-b-D-arabinofuranocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells. Schwendener RA, Friedl K, Depenbrock H, Schott H, Hanauske AR. Invest New Drugs 19(3): 203-10, 2001. PMID: 11561676

  85. Limited mycobacterial infection of the liver as a consequence of its microanatomical structure causing restriction of mycobacterial growth to professional phagocytes. Seiler P, Schwendener RA, Bandermann S, Brinkmann V, Grode L, Kaufmann SH, Aichele P., Infect Immun 69(12): 7922-7926, 2001. PMID: 11705978

  86. Roles of macrophages in measles virus infection of genetically modified mice. Roscic-Mrkic B, Schwendener RA, Odermatt B, Zuniga A, Pavlovic J, Billeter MA, Cattaneo R., J Virol 75(7): 3343-3351, 2001. PMID: 11238860

  87. Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris. Marty C, Scheidegger P, Ballmer-Hofer K, Klemenz R, Schwendener RA., Protein Expr Purif 21(1):156-164, 2001. PMID: 11162401

  88. Induction of cell cycle-dependent cytotoxicity and apoptosis by new heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine in PC-3 human prostate cancer cells. Cattaneo-Pangrazzi RM, Schott H, Wunderli-Allenspach H, Derighetti M, Schwendener RA. Biochem Pharmacol 60(12): 1887-1896, 2000. PMID: 11108805

  89. In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Ludewig B, Barchiesi F, Pericin M, Zinkernagel RM, Hengartner H, Schwendener RA. Vaccine 19(1): 23-32, 2000. PMID: 10924783

  90. The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145. Cattaneo-Pangrazzi RM, Schott H, Schwendener RA. The Prostate 45(1): 8-18, 2000. PMID: 10960838

  91. Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-b-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5'-->5')-N4-octadecyl-1-b-D-arabinofuranosylcytosine. Horber DH, Cattaneo-Pangrazzi RM, von Ballmoos P, Schott H, Ludwig PS, Eriksson S, Fichtner I, Schwendener RA. J Cancer Res Clin Oncol 126(6): 311-9, 2000. PMID: 10870640

  92. Cell-cycle arrest and p53-independent induction of apoptosis in vitro by the new anticancer drugs 5-FdUrd-P-FdCydOct and dCydPam-P-FdUrd in DU-145 human prostate cancer cells. Cattaneo-Pangrazzi RM, Schott H, Wunderli-Allenspach H, Rothen-Rutishauser B, Guenthert M, Schwendener RA. J Cancer Res Clin Oncol 126(5): 247-256, 2000. PMID: 10815759

  93. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. Ludewig B, Oehen S, Barchiesi F, Schwendener RA, Hengartner H, Zinkernagel RM. J Immunol 163: 1839-1844, 1999. PMID: 10438917

  94. Synthesis, in vitro anti-HIV and anti-hepatitis B activities and pharmacokinetic properties of amphiphilic heterodinucleoside phosphates containing ddC and AZT. Schwendener RA, Peghini PA, Ludwing PS, Schott H. Nucleosides Nucleotides 18(4-5): 949-950, 1999. PMID: 10432717

  95. Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-b-D-arabinofuranosyl cytosine in Daudi lymphoma cells. Koller-Lucae SK, Schott H, Schwendener RA. Br J Cancer 80(10): 1542-1549, 1999. PMID: 10408395

  96. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-b-D-arabinofuranosylcytosine in mice. Koller-Lucae SK, Suter MJ, Rentsch KM, Schott H, Schwendener RA. Drug Metab Dispos 27(3): 342-350, 1999. PMID: 10064564

  97. Toxicity of liposomal 3'-5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in mice. van Borssum Waalkes M, Goris H, Dontje BH, Schwendener RA, Scherphof G, Nijhof W. Anticancer Drug Des 13(4): 291-305, 1999. PMID: 9627669

  98. In vitro anti-human immunodeficiency virus and anti-hepatitis B virus activities and pharmacokinetic properties of heterodinucleoside phosphates containing AZT or ddC. Peghini PA, Zahner R, Kuster H, Schott H, Schwendener RA. Antivir Chem Chemother 9(2): 117-26, 1998. PMID: 9875383

  99. Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer. Rentsch KM, Schwendener RA, Pestalozzi BC, Sauter C, Wunderli-Allenspach H, Hänseler E. Eur J Clin Pharmacol 54(1): 83-89, 1998. PMID: 9591936

  100. Pharmacokinetics of N4-octadecyl-1-b-D-arabinofuranosyl cytosine in plasma and whole blood after intravenous and oral administration to mice. Rentsch KM, Schwendener RA, Schott H, Hänseler E. J Pharm Pharmacol 49(11): 1076-81, 1997. PMID: 9401941

  101. Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Seiler P, Aichele P, Odermatt B, Hengartner H, Zinkernagel RM, Schwendener RA. Eur J Immunol 27(10): 2626-33, 1997. PMID: 9368619

  102. Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-b-D-arabinofuranosyl cytosine, a new anticancer drug. Koller-Lucae SK, Schott H, Schwendener RA. J Pharmacol Exp Ther 282(3): 1572-80, 1997. PMID: 9316874

  103. Liposomal 1,25 (OH)2 vitamin D3 compounds block proliferation and induce differentiation in myelomonocytic leukaemia cells. Frankenberger M, Hofmann B, Emmerich B, Nerl C, Schwendener RA, Ziegler-Heitbrock HW. Br J Haematol 98(1): 186-94, 1997. PMID: 9233583

  104. Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. Rentsch KM, Horber DH, Schwendener RA, Wunderli-Allenspach H, Haenseler E. Br J Cancer 75(7): 986-92, 1997. PMID: 9083333

  105. Synthesis and in vitro antitumor Activity of 2'-deoxy-5-fluorouridylyl-(3'-5')-2'-deoxy-5-fluoro-N4-octadecylcytidine: A new amphiphilic Dinucleoside Phosphate. Schott H, Ludwig PS, Gansauge F, Gansauge S, Schwendener RA. (Eur. J. Org. Chem) Liebigs Annalen der Chemie 413-417 (1997).

  106. Synthesis of liposomal Phospholipid-(N4-palmitoyl-1-b-D-arabinofuranosylcytosine)-Conjugates and Evaluation of their cytostatic Activity against L1210 murine Leukemia. Schott, H. and Schwendener, R.A. (Eur. J. Org. Chem) Liebigs Annalen der Chemie 365-369 (1996).

  107. Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-b-D-arabinofuranosyl cytosine conjugates. Schott H, Schwendener RA. Anticancer Drug Des 11(6): 451-62, 1996. PMID: 8836110

  108. Determination of mitoxantrone in mouse whole blood and different tissues by high-performance liquid chromatography. Rentsch KM, Schwendener RA, Haenseler E. J Chromatogr B Biomed Appl 679: 185-92, 1996. PMID: 8998559

  109. Lipophilic 1-b-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. Schwendener RA, Schott H. J Cancer Res Clin Oncol 122(12): 723-6, 1996. PMID: 8954169

  110. Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-b-D-arabinofuranosyl cytosine. Schwendener RA, Horber DH, Odermatt B, Schott H. J Cancer Res Clin Oncol 122(2): 102-8, 1996. PMID: 8576276

  1. Sensitive high-performance liquid chromatographic method for the determination of N4-hexadecyl- and N4-octadecyl-1-b-D-arabinofuranosyl cytosine in plasma and erythrocytes. Rentsch KM, Schwendener RA, Schott H, Haenseler E. J Chromatogr B Biomed Appl 673(2): 259-66, 1995. PMID: 8611960

  2. Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-b-D-arabinofuranosyl cytosine. Horber DH, von Ballmoos P, Schott H, Schwendener RA. Br J Cancer 72(5): 1067-73, 1995. PMID: 7577448

  3. Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Pestalozzi BC, Vass A, Adam H, Horber DH, Schwendener RA, Sauter C. Eur J Cancer 31A(6): 1024, 1995. PMID: 7646906

  4. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-b-D-arabinofuranosylcytosine, a lipophilic derivative of 1-b-D-arabinofuranosyl cytosine. Horber DH, Schott H, Schwendener RA. Br J Cancer 71(5): 957-62, 1995. PMID: 7734320

  5. Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-b-D-arabinofuranosyl cytosine (NHAC) incorporated into liposomes. Horber DH, Ottiger C, Schott H, Schwendener RA. J Pharm Pharmacol 47(4): 282-8, 1995. PMID: 7791024

  6. Cellular pharmacology of N4-hexadecyl-1-b-D-arabinofuranosyl cytosine in the human leukemic cell lines K-562 and U-937. Horber DH, Schott H, Schwendener RA. Cancer Chemother Pharmacol 36(6): 483-92, 1995. PMID: 7554040

  7. Synthesis and in vitro antiviral properties of amphiphilic dinucleoside phosphate derivatives of 2',3'-dideoxycytidine (ddC). Schott H, Haeussler MP, Gowland P, Bender A, von Briesen H, Schwendener RA. Antivir. Chem. Chemother. 6: 320, 1995. doi:10.1177/095632029500600506

  8. Preclinical Properties of N4-hexadecyl- and N4-octadecyl-1-b-D-arabinofuranosylcytosine in liposomal Preparations. Schwendener RA, Horber DH, Ottiger C, Schott H. J. Liposome Res. 5: 27-47, 1995.

  9. Monograph: Alkasar-18, 1-(b-D-arabinofuranosyl)-4-octadecylamino-2(1H)-pyrimidin-one, N4-octadecyl-ara-C, NOAC. Schwendener RA, Horber, DH, Ottiger C, Rentsch KM, Fiebig HH, Schott, H. Drugs of the Future 20: 11-15, 1995.

  10. Time-resolved flow cytometry for the measurement of lanthanide chelate fluorescence: I. Concept and theoretical evaluation. Condrau MA, Schwendener RA, Niederer P, Anliker M. Cytometry 16(3): 187-94, 1994. PMID: 7924687

  11. Time-resolved flow cytometry for the measurement of lanthanide chelate fluorescence: II. Instrument design and experimental results. Condrau MA, Schwendener RA, Zimmermann M, Muser MH, Graf U, Niederer P, Anliker M. Cytometry 16(3): 195-205, 1994. PMID: 7924688

  12. New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens. Schwendener RA, Gowland P, Horber DH, Zahner R, Schertler A, Schott H. Antiviral Res 24(1): 79-93, 1994. PMID: 7944315

  13. Synthese von 4-Alkyl-cytosinnucleosiden und deren zytostatische Wirkung im L1210 Leukaemiemodell der Maus. Schott, H, Haeussler, MP, Schwendener, RA. (Eur. J. Org. Chem) Liebigs Annalen der Chemie, 465-470, 1994.

  14. Synthese und Eigenschaften von N4-hexadecyl-2' desoxycytidylyl-(3'-5')-5-ethyl-2'desoxyuridin und 2'-Desoxy-thymidylyl-(3'-5')-N4-hexadecyl-1-b-D-arabinofuranosylcytosin, zwei Vertreter einer neuen Prodrug-Gruppe. Schott, H, Haeussler, MP, Schwendener, RA. (Eur. J. Org. Chem) Liebigs Annalen der Chemie, 277-282, 1994.

  15. Liposomes as Carriers for paramagnetic Gadolinium Chelates as Organ specific Contrast Agents for magnetic Resonance Imaging (MRI). Schwendener RA. J. Liposome Res. 4: 837-855, 1994.

  16. Preclinical and clinical Experience with Liposome-encapsulated Mitoxantrone. Schwendener RA, Horber DH, Rentsch K, Haenseler E, Pestalozzi B, Sauter, C. J. Liposome Res. 4: 605-639, 1994.

  17. Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Pestalozzi B, Schwendener R, Sauter C. Ann Oncol 3(6): 445-9, 1992. PMID: 1498062

  18. Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-b-D-arabinofuranosyl cytosine. Schwendener RA, Schott H. Int J Cancer 51(3): 466-9, 1992. PMID: 1592536

  19. Schwendener, R.A., Liposomes and Immunoliposomes as Carriers for cytostatic Drugs, Magnetic Resonance Contrast Agents, and fluorescent Chelates. Chimia 46: 69-77, 1992.

  20. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. Schwendener RA, Fiebig HH, Berger MR, Berger DP. Cancer Chemother Pharmacol 27(6): 429-39, 1991. PMID: 2013113

  21. A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. Schwendener RA, Wuethrich R, Duewell S, Wehrli E, von Schulthess GK. Invest Radiol 25(8): 922-32, 1990. PMID: 2394576

  22. Comparative studies of the preparation of immunoliposomes with the use of two bifunctional coupling agents and investigation of in vitro immunoliposome-target cell binding by cytofluorometry and electron microscopy. Schwendener RA, Trueb T, Schott H, Langhals H, Barth RF, Groscurth P, Hengartner H. Biochim Biophys Acta 1026(1): 69-79, 1990. PMID: 2378882

  23. Small unilamellar Liposomes as Magnetic Resonance Contrast Agents loaded with paramagnetic Mn-, Gd-, and Fe-DTPA-stearate Complexes. Schwendener RA, Wuethrich R, Duewell S, Westera G, von Schulthess GK. Int. J. Pharmaceutics 49: 249-260, 1989.

  24. Discrepancy in the abilities of lymphokines and bacteria to mediate tumor protection in vivo and/or tumoricidal activity by macrophages in vitro. Keller R, Keist R, Schwendener RA. Int J Cancer 15;44(3): 512-7, 1989. PMID: 2506137

  25. Chromatography of functionalized liposomes and their components. Schott H, Leitner B, Schwendener RA, Hengartner H. J Chromatogr 441(1): 115-24, 1988. PMID: 3403675

  26. Palmitoyl derivatives of L-cysteine, cysteamine, L-cystine, cystamine and their incorporation into the bilayers of unilamellar liposomes. Schott H, Seeling R, Hengartner H, Schwendener RA. Biochim Biophys Acta 9; 940(1): 127-35, 1988. PMID:

  27. Incorporation of chlorpromazine into bilayer liposomes for protection against microsomal metabolism and liver absorption. Schwendener RA. Eur J Drug Metab Pharmacokinet 13(2): 135-41, 1988. PMID: 3208792

  28. The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes. Supersaxo A, Rubas W, Hartmann HR, Schott H, Hengartner H, Schwendener RA. J Microencapsul 5(1): 1-11, 1988. PMID: 2974073

  29. Liposomes as carriers of lipophilic cytosine arabinoside and fluorodeoxyuridine derivatives. Their cytostatic effect and possibilities of tumor cell specific therapy. Schwendener RA, Schott H, Hartmann HR, Supersaxo A, Rubas W, Hengartner H. Onkologie 10(4): 232-9, 1987. (German). PMID: 2959889

  30. (Na++ K+)-ATPase in artificial lipid vesicles: influence of lipid structure on pumping rate. Marcus MM, Apell HJ, Roudna M, Schwendener RA, Weder HG, Laeuger P. Biochim Biophys Acta 854(2): 270-8, 1986. PMID: 3002468

  31. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Rubas W, Supersaxo A, Weder HG, Hartmann HR, Hengartner H, Schott H, Schwendener R. Int J Cancer 15; 37(1): 149-54, 1986. PMID: 3941019

  32. The preparation of large volumes of homogeneous, sterile liposomes containing various lipophilic cytostatic drugs by the use of a capillary dialyzer. Schwendener RA. Cancer Drug Deliv 3(2): 123-9, 1986. PMID: 2939941

  33. 5'-O-Palmitoyl- and 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine--novel lipophilic analogues of 5'-fluoro-2'-deoxyuridine: synthesis, incorporation into liposomes and preliminary biological results. Schwendener RA, Supersaxo A, Rubas W, Weder HG, Hartmann HR, Schott H, Ziegler A, Hengartner H. Biochem Biophys Res Commun 126(2): 660-6, 1985. PMID: 3156589

  34. The effects of charge and size on the interaction of unilamellar liposomes with macrophages. Schwendener RA, Lagocki PA, Rahman YE. Biochim Biophys Acta 772(1): 93-101, 1984. PMID: 6712952

  35. n-Alkyl-glucosides as detergents for the preparation of highly homogeneous bilayer liposomes of variable sizes (60-240 nm) applying defined rates of detergent removal by dialysis. Schwendener RA, Asanger M, Weder HG. Biochem Biophys Res Commun 100(3): 1055-62, 1981. PMID: 7271790

  36. The preparation of large single bilayer liposomes by a fast and controlled dialysis. Milsmann MH, Schwendener RA, Weder HG. Biochim Biophys Acta 512(1): 147-55, 1978. PMID: 698210

  37. The binding of chlorpromazine to bilayer liposomes. Evaluation of stoichiometric constants from equilibrium and steady state studies. Schwendener RA, Weder HG. Biochem Pharmacol 27(23): 2721-7, 1978. PMID: 569488

Go to the other pages:
Last update of this page on  

.....Thanks for your visit, .....Bye.
Back to Top